MEMPHASYS LIMITED. — Regulatory Filings 2012

Mar 5, 2012

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

NuSep signs Distribution Agreement with In Vitro Technologies & Clarification of Earlier Announcement

Sydney, Australia 6[th] March 2012 - NuSep (ASX: NSP) is pleased to advise the market that it has signed a distribution agreement with In Vitro Technologies for the sale of NuSep consumable products into the Australia and New Zealand markets. In Vitro Technologies (www.invitro.com.au) is a Scientific and Medical distribution company specialising in the sale and support of scientific, clinical diagnostic, medical and related products, with its head office in Melbourne. In Vitro Technologies has offices throughout Australia and New Zealand.

In Vitro Technologies has an established customer base in the local Protein Expression & Detection markets and NuSep nUView Gels range provide a natural complementary fit with their existing product ranges.

NuSep estimates that the Australian Analytical Gel market is worth $2.5m pa. Dr Hari Nair, Managing Director of NuSep noted that “distribution is the key to expanding NuSep’s sales. The ability to partner with a respected distributor means that NuSep will be able to expand its market penetration of its nUView gels in Australia”.

“We’re delighted to be working with In Vitro Technologies to further boost the NuSep brand into the local market,” said NuSep Managing Director Dr Hari Nair. “We’re working with a high quality partner who will be able to maintain the integrity and positioning of our premium brand.”

Jennifer Parsons, Managing Director of In Vitro Technologies said that “the addition of Nusep to our portfolio of quality life science products increases our ability to serve our customer base. It reflects our strategy to provide premium products, reliable service and scientific technical support to add value to our customer’s work. We look forward to a long and mutually beneficial business partnership with NuSep”

Transfer of Shares in Suspense

The Company advised the market on 12 December 2011 that the Company had made ASIC aware of certain breaches of the Corporations Act. The Company also noted that ASIC had not indicated an intention to take any action against the Company or any other person in connection with the breaches. Whilst this is correct and no action has been taken by ASIC to date, for the purposes of clarification, the Company advises that

NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066

Contact Details Email info@nusep.com Telephone +61 2 8415 7300 Web www.nusep.com Facsimile +61 2 8415 7399 ABN 33 120 047 556

Postal Address P.O. Box 823 Lane Cove NSW 1595

– 2 –

ASIC did advise that the Company that it reserves its rights to take action in relation to the contraventions.

ENDS

For more information please contact:

Contact: Tom Rowe Company Secretary +61 2 8415 7300 tom.rowe@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 17] intentionally omitted <==

• Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company’s website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. PrIME Biologics is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

– 3 –

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many countries.

About In Vitro Technologies

In Vitro Technologies is a Scientific and Medical distribution company specialising in the sale and support of scientific, clinical diagnostic, medical and related products. The company was established in 2002 and is 100% owned by JJ Richards & Sons Pty Ltd. JJ Richards & Sons Pty Ltd was established in 1932 and is the largest privately owned waste and environmental management company in Australia, with revenues in excess of $300 million and employing over 1,200 employees throughout Australia and New Zealand.

In Vitro Technologies has quickly developed a reputation for being one of the most dynamic and successful companies in the Australian scientific, diagnostic, medical and laboratory consumable supplies and equipment. The company's first acquisition was that of Biotek Ltd in early 2003. Biotek, based in Auckland, has operated in New Zealand for over 20 years as a national distributor for medical and clinical diagnostic products. In 2004 In Vitro Technologies acquired Medos. Medos was established in 1958 and has been a well-known supplier in the Australian scientific and medical market for over 45 years.